CRVO
$4.53
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Recent News
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.